Show simple item record

Proficiency of nerve conduction using standard methods and reference values (cl. NPhys Trial 4)

dc.contributor.authorLitchy, William J.en_US
dc.contributor.authorAlbers, James W.en_US
dc.contributor.authorWolfe, Jamesen_US
dc.contributor.authorBolton, Charles F.en_US
dc.contributor.authorWalsh, Nancyen_US
dc.contributor.authorKlein, Christopher J.en_US
dc.contributor.authorZafft, Andrew J.en_US
dc.contributor.authorRussell, James W.en_US
dc.contributor.authorZwirlein, Melanieen_US
dc.contributor.authorOverland, Carol J.en_US
dc.contributor.authorDavies, Jenny L.en_US
dc.contributor.authorCarter, Rickey E.en_US
dc.contributor.authorDyck, Peter J.en_US
dc.date.accessioned2014-12-09T16:53:57Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-12-09T16:53:57Z
dc.date.issued2014-12en_US
dc.identifier.citationLitchy, William J.; Albers, James W.; Wolfe, James; Bolton, Charles F.; Walsh, Nancy; Klein, Christopher J.; Zafft, Andrew J.; Russell, James W.; Zwirlein, Melanie; Overland, Carol J.; Davies, Jenny L.; Carter, Rickey E.; Dyck, Peter J. (2014). "Proficiency of nerve conduction using standard methods and reference values (cl. NPhys Trial 4)." Muscle & Nerve 50(6): 900-908.en_US
dc.identifier.issn0148-639Xen_US
dc.identifier.issn1097-4598en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/109629
dc.description.abstractIntroduction The Cl. NPhys Trial 3 showed that attributes of nerve conduction (NC) were without significant intraobserver differences, although there were significant interobserver differences. Methods : Trial 4 tested whether use of written instructions and pretrial agreement on techniques and use of standard reference values, diagnostic percentile values, or broader categorization of abnormality could reduce significant interobserver disagreement and improve agreement among clinical neurophysiologists. Results : The Trial 4 modifications markedly decreased, but did not eliminate, significant interobserver differences of measured attributes of NC. Use of standard reference values and defined percentile values of abnormality decreased interobserver disagreement and improved agreement of judgment of abnormality among evaluators. Therefore, the same clinical neurophysiologist should perform repeat NCs of therapeutic trial patients. Conclusions : Differences in interobserver judgment of abnormality decrease with use of common standard reference values and a defined percentile level of abnormality, providing a rationale for their use in therapeutic trials and medical practice. Muscle Nerve 50: 900–908, 2014en_US
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherElsevieren_US
dc.subject.otherMulticenter Trialen_US
dc.subject.otherNerve Conduction Accuracyen_US
dc.subject.otherNeuropathy Impairment Scoreen_US
dc.subject.otherReference Valuesen_US
dc.subject.otherNerve Conduction Proficiencyen_US
dc.titleProficiency of nerve conduction using standard methods and reference values (cl. NPhys Trial 4)en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/109629/1/mus24243.pdf
dc.identifier.doi10.1002/mus.24243en_US
dc.identifier.sourceMuscle & Nerveen_US
dc.identifier.citedreferenceKimura J. Nerve conduction and needle electromyograpy. In: Dyck PJ, Thomas PK, editors. Peripheral neuropathy, 4th ed. Vol. 1. Philadelphia: Elsevier; 2005. p 899 – 970.en_US
dc.identifier.citedreferenceDyck PJ, Albers JW, Wolfe J, Bolton CF, Walsh N, Klein CJ, et al. A trial of proficiency of nerve conduction: greater standardization still needed. Muscle Nerve 2013; 48: 369 – 374.en_US
dc.identifier.citedreferenceZiegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, et al. Efficacy and safety of antioxidant treatment with alpha‐lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 Trial. Diabetes Care 2011; 34: 2054 – 2060.en_US
dc.identifier.citedreferenceZiegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. Oral treatment with alpha‐lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29: 2365 – 2370.en_US
dc.identifier.citedreferenceApfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy. A randomized controlled trial. JAMA 2000; 284: 2215 – 2221.en_US
dc.identifier.citedreferenceDyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11: 136 – 141.en_US
dc.identifier.citedreferenceSchifitto G, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, et al. Long‐term treatment with recombinant nerve growth factor for HIV‐associated sensory neuropathy. Neurology 2001; 57: 1313 – 1316.en_US
dc.identifier.citedreferenceThompson PD, Thomas PK. Clinical patterns of peripheral neuropathy. In: Dyck PJ, Thomas PK, editors. Peripheral neuropathy, 4th ed. Philadelphia: Elsevier; 2005. p 1137 – 1162.en_US
dc.identifier.citedreferenceChaudhry V, Cornblath DR, Mellitis ED, Avila O, Freimer ML, Glass JD, et al. Inter‐ and intra‐examiner reliability of nerve conduction measurements in normal subjects. Ann Neurol 1991; 30: 841 – 843.en_US
dc.identifier.citedreferenceDyck PJ, Argyros B, Russell JW, Gahnstrom L, Naleppa S, Albers JW, et al. Multicenter trial of the proficiency of smart quantitative sensation tests. Muscle Nerve 2013 Aug 8. [Epub ahead of print]. PMID: 23929701. DOI: 10.1002/mus.23982.en_US
dc.identifier.citedreferenceDyck PJ, Overland CJ, Low PA, Litchy WJ, Davies JL, Dyck PJB, et al. "Unequivocally abnormal" vs. "usual" signs and symptoms for proficient diagnosis of diabetic polyneuropathy Cl vs. N Phys Trial. Arch Neurol 2012; 69: 1609 – 1614.en_US
dc.identifier.citedreferenceDyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of healthy subjects (RDNS‐HS). Neurology 1995; 45: 1115 – 1121.en_US
dc.identifier.citedreferenceDyck PJ, Overland CJ, Low PA, Litchy WJ, Davies JL, Dyck PJB, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys Trial. Muscle Nerve 2010; 42: 157 – 164.en_US
dc.identifier.citedreferenceSuanprasert N, Berk JL, Benson MD, Dyck PJB, Klein CJ, Gollob JA, et al. Toward representative quantitation of neuropathy signs and tests in transthyretin amyloidosis. 2014 (in preparation).en_US
dc.identifier.citedreferenceGrant IA, Benstead TJ. Differential diagnosis of polyneuropathy. In: Dyck PJ, Thomas PK, editors. Peripheral neuropathy, 4th ed. Vol. 1. Philadelphia: Elsevier; 2005. p 1163 – 1180.en_US
dc.identifier.citedreferenceSmith BE, Windebank AJ, Dyck PJ. Nonmalignant inflammatory sensory polyganglionopathy. In: Dyck PJ, Thomas PK, editors. Peripheral neuropathy, 4th ed. Philadelphia: Elsevier Saunders; 2005. p 2309 – 2320.en_US
dc.identifier.citedreferenceBerk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310: 2658 – 2667.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.